IntelGenx to Double in Value Next Year
On Thursday, IntelGenx, a drug delivery development company that produces and sells pharmaceutical films such as VersaFilm and transdermal VevaDerm, reported its Q4 full year 2020 financials, reporting fourth-quarter sales of $790,000 with an adjusted EBITDA loss of $754,000.
After IntelGenx Technologies’ recent fourth-quarter report, Douglas Loe, an analyst at Leede Jones Gable, is optimistic about the venture. Loe disclosed a C$1.00 target price in an update to investors, representing a forecast one-year return of 100% at the time of publishing….